読み込み中
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.
前日終値
$13.81
+$0.06 · +0.44%
日中の時刻はETです。市場データは遅延する場合があります。
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.
日中レンジ
現在 $13.81
52週レンジ
現在 $13.81
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
88
大幅な割安
センチメント
67
強気
リスク
13
低リスク
モメンタム
53
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Organon & Co., a global pharmaceutical enterprise, is dedicated to developing and delivering a wide array of prescription therapies. Its women's health division features reproductive care products, encompassing birth control and fertility treatments, notably Nexplanon/Implanon, an extended-duration contraceptive. The company's biosimilars collection includes three immune-related medications (Brenzys, Renflexis, Hadlima) and two cancer therapies (Ontruzant, Aybintio). Additionally, Organon provides cardiovascular medications, such as cholesterol-reducing drugs (Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, Zocor) and treatments for high blood pressure (Cozaar, Hyzaar). Their respiratory product line addresses asthma symptoms with brands like Singulair, Dulera, Zenhale, and Asmanex, and manages seasonal allergies through Singulair, Nasonex, Clarinex, and Aerius. Furthermore, their offerings extend to dermatological care (Diprosone, Elocon), bone strengthening (Fosamax), and non-narcotic pain relief (Arcoxia, Diprospan, Celestone). The portfolio also comprises Proscar for treating symptomatic benign prostatic hyperplasia and Propecia for combating male pattern hair loss. The company's products are primarily distributed to pharmaceutical wholesalers, retailers, medical facilities, government entities, and various managed healthcare organizations, including health maintenance organizations and pharmacy benefit managers. Organon & Co. was established in 2020 and is headquartered in Jersey City, New Jersey.
日中レンジ
現在 $13.81
52週レンジ
現在 $13.81
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 62.16億 USD | 64.03億 USD | 62.63億 USD | 61.74億 USD | 63.04億 USD |
| 売上原価 | 28.54億 USD | 26.88億 USD | 25.15億 USD | 22.94億 USD | 23.82億 USD |
| 粗利益 | 33.62億 USD | 37.15億 USD | 37.48億 USD | 38.8億 USD | 39.22億 USD |
| 研究開発 | 3.66億 USD | 4.69億 USD | 5.28億 USD | 4.71億 USD | 4.43億 USD |
| 販売・一般管理 | 17.11億 USD | 17.6億 USD | 18.93億 USD | 17.04億 USD | 16.68億 USD |
| 営業費用 | 20.87億 USD | 22.29億 USD | 24.21億 USD | 21.75億 USD | 20.07億 USD |
| 支払利息 | 5.04億 USD | 5.2億 USD | 5.27億 USD | 4.22億 USD | 2.58億 USD |
| 減価償却費と償却費 | 3.61億 USD | 2.77億 USD | 2.36億 USD | 2.12億 USD | 1.95億 USD |
| 営業利益 | 12.85億 USD | 14.86億 USD | 13.27億 USD | 17.05億 USD | 19.15億 USD |
| 純利益 | 1.87億 USD | 8.64億 USD | 10.23億 USD | 9.17億 USD | 13.51億 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$14.00
上昇余地（1.38%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI1.15億0.00%2.3兆 USD0.03%$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB8307.28万0.04%1853億 USD0.03%$289.48+0.64%
Vanguard Morningstar Small-Cap Value ETFVBR5279.97万0.08%682億 USD0.05%$234.43+0.22%
Vanguard Extended Market ETFVXF4198.17万0.04%954億 USD0.05%$235+0.80%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM3327.74万0.21%158.4億 USD0.03%$53.45+0.17%
Schwab U.S. Small-Cap ETFSCHA1910.84万0.09%218.24億 USD0.03%$32.79+0.40%
State Street SPDR S&P 600 Small Cap Value ETFSLYV1888.1万0.40%47.36億 USD0.15%$103-0.30%
iShares Russell Mid-Cap ETFIWR1513.3万0.03%567.65億 USD0.18%$109.82+0.87%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Value ETFVBRVanguard Extended Market ETFVXFState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMSchwab U.S. Small-Cap ETFSCHAState Street SPDR S&P 600 Small Cap Value ETFSLYViShares Russell Mid-Cap ETFIWRAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
